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Abstract
Tumour angiogenesis is an important hallmark of cancer and the study of its metabolic
adaptations, downstream to any cellular change, can reveal attractive targets for inhibiting
cancer growth. In the tumour microenvironment, endothelial cells (ECs) interact with hetero-
geneous tumour cell types that drive angiogenesis and metastasis. In this study we aim to
characterize the metabolic alterations in ECs influenced by the presence of tumour cells
with extreme metastatic abilities. Human umbilical vein endothelial cells (HUVECs) were
subjected to different microenvironmental conditions, such as the presence of highly meta-
static PC-3M and highly invasive PC-3S prostate cancer cell lines, in addition to the angio-
genic activator vascular endothelial growth factor (VEGF), under normoxia. Untargeted high
resolution liquid chromatography-mass spectrometry (LC-MS) based metabolomics
revealed significant metabolite differences among the various conditions and a total of 25
significantly altered metabolites were identified including acetyl L-carnitine, NAD+, hypoxan-
thine, guanine and oleamide, with profile changes unique to each of the experimental condi-
tions. Biochemical pathway analysis revealed the importance of fatty acid oxidation and
nucleotide salvage pathways. These results provide a global metabolic preview that could
help in selectively targeting the ECs aiding in either cancer cell invasion or metastasis in the
heterogeneous tumour microenvironment.
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Introduction
Tumour microenvironment is a perfectly designed niche for cancer cells, in that they have
acquired the ability to break all the cellular rules and hijack the stromal cells for their survival
and propagation [1]. Tumour vascularization is considered as an essential system for cancer
proliferation and is crucial for providing oxygen and nutrients for survival, invasion and
enables metastasis to other distal locations [2]. Endothelial cells (ECs), like other stromal cells
such as cancer-associated fibroblasts and macrophages, can be reprogrammed by tumour-
released factors inducing angiogenesis [2]. As our knowledge of tumour angiogenesis expands,
its potential as an alternative target for cancer treatment is being increasingly explored and
could be considered complementary to the conventional treatments that target only the cancer
cells [3]. Clinical therapies targeting angiogenesis have been mostly aimed at inhibiting cellular
signalling and have only been partially successful [3]. Tumour-released factors can signifi-
cantly affect the ECs downstream angiogenic signalling, i.e. at the level of cellular metabolism
suggesting that they may be attractive targets for anti-cancer therapy [4]. General EC metabo-
lism has been described by some of the main central carbon metabolic pathways to include gly-
colysis, Kreb’s cycle and pentose phosphate pathway (PPP), while metabolic changes in the
tumour-driven EC growth have not as yet been extensively characterized [5]. In order to
understand the metabolic changes that affect angiogenesis associated with tumours it is impor-
tant to choose a method that can focus only on the affected ECs, which is different in vivo due
to the complexity associated with extracting different types of stromal cells from the tumour
tissues. The in vitro co-culture method employed in this study intends to explore specifically
the tumour-endothelial cell association. Previous studies on in vitro endothelial—tumour cell
interactions have been performed using different co-culture models and the cellular changes
were assessed in gene and protein expression analysis and cellular phenotypes [6–9]. However
metabolic changes due to this stromal-tumour cellular interaction are yet to be explored.
In this study we aim for the first time to characterize the global metabolic profile of ECs
under the influence of cancer cell sub-populations with differing metastatic abilities. To
achieve this we apply a high resolution mass spectrometry—based untargeted metabolomics
analysis which involves a generic extraction, chromatographic separation and detection of ana-
lyte ions, data pre-processing and analysis, followed by identification of interested metabolites
without a priori information [10]. Metabolite set enrichment analysis (MSEA) was used to
explore the metabolites highly enriched and associated with possible metabolic pathways [11]
and the results of metabolite changes and pathway enrichment obtained with each condition
are discussed in the following section. These results provide an overall preview of the meta-
bolic plasticity of ECs in the heterogeneous tumour microenvironment, which could be
exploited in combined therapies targeting not only the tumour cell reprogramming, but also
the metabolic changes of ECs induced by the tumour microenvironment.
Materials and methods
Cell culture conditions
Human umbilical vein endothelial cells (HUVECs), purchased from Lonza (CC-2519) were
maintained in 1% gelatin coated flasks at 37˚C in a humidified atmosphere of 5% CO2 and
95% air in MCDB131 (Gibco) complete medium supplemented with recommended quantity
of endothelial growth medium SingleQuots (EGM) (Lonza), 10% fetal bovine serum (FBS)
(Gibco), 2 mM glutamine (Gibco) and 1% streptomycin (100 μg/mL)/penicillin (100 units/
mL) (S/P, Gibco). The prostate cancer cell sub-populations, PC-3M and PC-3S were clonally
derived from the human cell line PC-3 [12]. These cells were maintained at 37˚C in a 5% CO2
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atmosphere in RPMI 1640 (Sigma-Aldrich or Biowest) complete medium supplemented with
10 mM glucose and 2 mM glutamine, 10% FBS (PAA Laboratories), 1% pyruvate (1 mM) (Bio-
logical Industries), 1% S/P and 1% nonessential amino acids (Biological Industries).
Co-culture experiments: Conditions and procedure
HUVECs were seeded in 6-well plates (Falcon) in MCDB131 complete medium, and after 6h
they were deprived of nutrients/hormones with restricted medium (RM) consisting of DMEM
with 5.56 mM glucose (Sigma) supplemented with 2% FBS, 2 mM glutamine and 0.1% strepto-
mycin/penicillin, overnight. Simultaneously, PC-3M and PC-3S cells were seeded in cell cul-
ture inserts supported in separate 6-well plates (Falcon) in RPMI complete medium. After 24h
all the cells were washed with PBS and RM was added to both HUVECs and PC-3M and PC-
3S cells, and inserts placed over the wells for the co-culture incubation. For the VEGF condi-
tion, HUVECs were maintained in the 6-well plates in RM supplemented with 30 ng/mL of
Human vascular endothelial growth factor 165 (VEGF165, Miltenyi Biotec) and control
HUVECs were maintained only with the RM. Following a 24h incubation of the control and
the experimental conditions under normoxia (21% O2, 5% CO2) at 37˚C in a humidified atmo-
sphere, the HUVECs in the wells (n = 3 biological replicates) were trypsinized and the pellets
stored at -80˚C until extraction.
Sample preparation
500 μL of 50% ice-cold MeOH/water was added to the frozen cell pellets and 25 μL of 0.001
mg/mL of tryptophan D3 (internal standard) was added to all the samples prior to extraction.
Samples were mixed using a microplate shaker for 10 min, followed by ultrasonication at 4˚C
for 20 min and mixed again using a microplate shaker for 10 min. Samples were subsequently
centrifuged at 13,000 g at 4˚C for 20 min and the supernatant collected. The supernatant was
evaporated to dryness under vacuum at room temperature and reconstituted in 150 μL of
ultra-pure water. The sample extract was filtered using Whatmann syringeless filters (0.2 μm)
and the filtrate transferred to a maximum recovery vial for analysis. 5 μL was injected onto the
LC/MS (Dionex 3000, Thermo Scientific; n = 3 technical replicates). For quality control, a
pooled sample was made from all samples together and injected at intervals of every 10 sam-
ples throughout the entire experiment to determine the chromatographic reproducibility of
retention times and peak intensities, and was used for fragmentations later [13, 14].
LTQ—Orbitrap Elite LC/MS analysis
Dionex 3000 Ultra High Performance Liquid Chromatography (UHPLC) coupled with an
Orbitrap Elite was used for acquiring the data. The chromatographic system was coupled to
the mass spectrometer with a heated electrospray ionization source II (HESII). The optimized
HESII conditions for both ESI+ and ESI- were: spray voltage of 3.5 kV; sheath gas flow rate
(N2), 60 units; auxiliary gas flow rate, 45; sweep gas flow rate, 1; capillary temperature, 320˚C;
S lens RF level, 35; heater temperature, 400˚C. Nitrogen produced by a nitrogen generator
(Peak Scientific) was employed as both the collision and damping gas. Orbitrap mass calibra-
tion was performed once a week to ensure a working mass accuracy of< 5 ppm. Pierce LTQ
Velos ESI Positive ion and Pierce LTQ Velos ESI Negative ion calibration solutions from
Thermo Fisher Scientific (Rockford, IL, USA) were used to calibrate the mass spectrometer. A
mass range of 50–1200 m/z and resolving power of 60,000 FWHM at 400 m/z were used for
full scan acquisitions. Data dependent acquisitions with an MS/MS list incorporating precur-
sor ion accurate mass and retention time were used for identification experiments. The precur-
sor ions were isolated in the LTQ at an isolation width of 1 m/z, fragmented in the HCD cell
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and analysed in the Orbitrap at a mass range of 100–750 m/z and resolving power of 60,000
FWHM at 400 m/z. The fragmentation was completed at 4 different collision energies, NCE–
10, 30, 50 and 70%. The chromatographic column used was an Acquity BEH C18, 1.7 um 2.1 x
100 mm (Waters, Wexford Ireland) and the mobile phases used were 0.1% formic acid in
water (A) and 0.1% formic acid in methanol (B). The ESI+ gradient was as follows, (time in
minutes, %B): (0, 1), (2.5, 1), (16, 99), (18, 99), (18.11, 1), (20, 1) with a flow rate of 0.4 ml/min.
ESI- employed the same gradient with a flow rate of 0.36 ml/min.
Data analysis
Xcalibur 2.2 from Thermo Fisher Scientific (MA, USA) was used for instrument control and
acquisition of the high resolution LC-MS data. The acquired .raw files were converted to .
mzML format using the Proteowizard msconvert tool [15]. The data were uploaded to XCMS
online for data pre-processing and analysis. The pre-processing parameters used are as follows:
feature detection with centWave (m/z tolerance of 5 ppm, minimum and maximum peak
widths of 5 and 20 respectively), retention time correction with obiwarp method (profStep1),
chromatographic alignment with mzwid—0.05, minfrac 0.5 and bw 5. The multi-group data
analysis was undertaken using the Kruskal-Wallis non-parametric test with post hoc analysis
[16]. Peak intensities were normalized against cell counts and column plots for statistically sig-
nificant metabolites were plotted. The top 200 features were selected from the variable impor-
tance in projection (VIP) plots based on their importance to each respective model, which
were further short-listed by cross checking their chromatographic peak shapes, peak intensities
and p-values from their corresponding spectral profiles in XCMS Online. Significant features
with p-value 0.05, q-value 0.05 and peak intensity 105 were chosen for identification.
The short-listed ions were fragmented (MS/MS) and metabolite identifications were con-
firmed by comparing with standards in the high resolution mass spectral library, mzCloud
(https://www.mzcloud.org). Multivariate analysis (orthogonal projection to partial least
squares discriminant analysis; OPLS-DA) was completed in SIMCA v14.1 (Umetrics, Umea,
Sweden) to visualize differences between sample groups and to produce the prediction models.
The identified features and their peak areas were analysed using the MSEA tool, which is simi-
lar to the gene set enrichment analysis (GSEA), through the MetaboAnalyst 3.0 software [11,
17], where a biologically meaningful pattern was estimated for our identified metabolites using
a pre-defined set of metabolites, associated to the metabolic pathways. Peak area data (S1
Table) was uploaded pairwise, as conditions of control (RM) vs. VEGF, PC-3S or PC-3M co-
cultured HUVECs. In this case a quantitative enrichment analysis (QEA) was carried out with
the peak area data, associated with the identified metabolites, uploaded into the web-based
software and a Q-statistic was estimated for each metabolite set that describes the correlation
between the peak area profiles, X, of the matched metabolite set and the phenotype labels, Y,
which in our case are the different conditions of HUVECs with RM, VEGF, PC-3S and PC-3M
cells. Fold enrichment obtained from the MetaboAnalyst application of MSEA is calculated as
the ratio of calculated statistic/expected statistic [18, 19]. Statistical significance for the bar
graphs were obtained by calculating p-values, represented by:  p 0.05,  p 0.01, 
p 0.001,  p 0.0001.
Results
We report differential responses of ECs to heterogeneous tumour cell subpopulations, using
HUVECs which were co-cultured with prostate cancer cell sub-populations exhibiting extreme
metastatic abilities. For this purpose we have used a dual model cell lines derived from the PC-
3 cells [12], in which the PC-3M is enriched with epithelial cancer stem cell (CSC) properties,
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while the PC-3S model lacks this feature (non-CSC) but displays a stable epithelial mesenchy-
mal transition (EMT). We have done an extensive characterization of the CSC features of PC-
3M cell line model [12], substantiated by its expression of genetic markers characteristic of
stem cells [20, 21]. The completely disconnected properties of CSC and EMT in these cell
lines, regardless of their tissue of origin, provides us with ideal models for studying their meta-
bolic influences on ECs based on their distinct metastatic abilities.
The LC/MS data was analysed using XCMS Online which identified 5285 features in ESI
+ and 1366 features in ESI- by multi-group analysis, based on retention time and m/z value
matches. Multivariate data analysis for all conditions was performed using OPLS-DA (Fig 1).
The ESI+ data showed cumulative values of R2(Y) = 99.7% and Q2 = 86.2% and ESI- showed
R2(Y) = 97.9% and Q2 = 86.3%, where R2 indicates the variation shown by all the components
in the model and Q2 is the accuracy of the model prediction of the class membership. These
high values indicate excellent clustering of the groups whilst also demonstrating a clear distinc-
tion between control HUVECs and HUVECs submitted to each of the treatment conditions
(VEGF, PC-3S cells or PC-3M cells), except PC-3S condition in the ESI- mode.
The detailed fragmentation spectra and the matching spectral profile from the mass spectral
library for each of the identified metabolites are shown in S1 Fig. In this study, a quantitative
metabolite identification metric was adapted based on the study by Sumner et. al., 2014 [22],
to increase the confidence in identification, for which a minimum identification point (IP) of
5 is suggested. In this work the following features were considered to calculate the IP score:
accurate mass match with a tolerance of 5 ppm (1.0 IP), accurate mass tandem mass spectrum
(2.0 IP), and molecular formula from accurate mass and isotopic pattern (1.0 IP). The total
score for each metabolite is calculated as, (1+2+1)1.5 = 6 (the score is multiplied by 1.5 for
spectral library match or 2 for the use of standards). Thus by performing fragmentation of the
short-listed ions and comparing the resulting spectra with the mass spectral library a list of the
putatively identified metabolites were generated, that are displayed in Table 1. It can be
observed that, while the ESI+ mode can detect higher number of features and metabolites,
both ESI+ and ESI- modes of acquisition provide complementary information and different
sets of metabolites, except for the redundancy observed in L-glutamic acid, pantothenic acid
and L-glutathione (normalized peak areas are shown in S1 Table).
The quantitative MSEA [18] of the peak area profiles (S1 Table) revealed that the majority
of the metabolic pathways that are significantly altered in HUVECs in response to VEGF are
shared with variations observed upon co-culture with PC-3S cells (Fig 2). These include
Fig 1. Orthogonal projection to partial least squares discriminant analysis (OPLS-DA) plots: (a) ESI+ ionization mode, (b) ESI-
ionization mode. RM_24h –Control HUVECs incubated in restricted medium for 24h, V_24h—HUVECs with VEGF, M_24h –
HUVECs co-cultured with PC-3M cells, S_24h –HUVECs co-cultured with PC-3S cells.
https://doi.org/10.1371/journal.pone.0192175.g001
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pathways related to fatty acid β-oxidation (associated with acetyl L-carnitine, ALC) and glycol-
ysis, nicotinate and nicotinamide metabolism, citric acid cycle, ketone body metabolism and
gluconeogenesis (all of which are related to nicotinamide dinucleotide, NAD). Not all meta-
bolic pathways were equally altered in both conditions. Thus, VEGF, but not PC-3S co-culture,
induced a significant change in purine metabolism (hypoxanthine, guanine and adenosine
monophosphate (AMP)), while co-culture with PC-3S cells, but not VEGF, significantly
altered glutathione, pantothenate and amino acid metabolism.
Contrastingly, HUVECs co-cultured with the highly metastatic PC-3M cells exhibited a
metabolic profile completely distinct from that observed in response to VEGF or co-culture
with PC-3S cells (Fig 2). The tryptophan, phenylalanine, tyrosine, catecholamine, methionine
Table 1. Putative metabolite identifications with ESI+ and ESI- modes.
ESI+
Identified metabolites Accurate mass from XCMS online [M+H] Retention time (min) p-value
L-Glutamic acid 148.0600 0.70 0.00509
L-Arginine 175.1182 0.65 0.00007
L-Glutathione reduced 308.0900 1.15 0.00067
L-Tryptophan 205.0965 5.30 0.00001
L-Tyrosine 182.0805 1.49 0.00002
Methionine 150.0579 1.13 6.07226e-6
Nicotinamide dinucleotide (NAD) 664.1141 1.30 7.25358e-6
Pantothenic acid 220.1173 5.09 0.00004
Oleamide 282.2781 16.32 0.00342
γ-L-Glutamyl-L-Glutamic acid 277.1021 0.93 0.00125
Inosine 269.0873 2.71 0.00291
Spermine 203.2223 0.51 ns
trans 3-Indole acrylic acid/Indole 3-acrylic acid 188.0700 5.30 0.00001
Cysteinylglycine 179.0479 1.15 0.00046
Guanine 152.0561 0.91 0.00017
Creatine 132.0763 0.73 0.0005
Hypoxanthine 137.0453 1.19/2.71 0.00007/0.00401
Acetyl L-Carnitine (ALC) 204.1222 1.01 1.66321e-6
ESI-
Identified metabolites Accurate mass from XCMS online [M-H] Retention time (min) p-value
L-Aspartate 132.0298 0.74 0.01284
L-Glutamic acid# 146.0454 0.75 ns
Glycerol 3-phosphate 171.0058 0.82 ns
Pantothenic acid# 218.1026 5.26 0.00013
Uridine 243.0613 1.72 0.00445
L-Glutathione reduced# 306.0752 1.24 0.00052
Uridine monophosphate 323.0273 1.10 0.04184
Adenosine monophosphate 346.0544 1.11 ns
Galactonic acid 195.0503 0.76 ns
Guanosine 282.0834 2.82 0.01496
Hypoxanthine shows two isotopic peaks at the same accurate mass.
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and betaine metabolic pathways were found to be significantly affected, while none of the
major pathways affected in HUVECs by VEGF stimulation and/or PC-3S co-culture were sig-
nificantly affected by PC-3M co-culture (Fig 2).
Although the MSEA-based metabolite pathway enrichment arranges the identified metabo-
lites into meaningful metabolic pathways, it does not provide information about the direction
(upregulation or downregulation) of the enrichment. In order to complement this analysis,
bar graph models were constructed for the peak areas of the identified metabolites, incorporat-
ing them into the pathways shown as altered in MSEA. These models show that ALC was upre-
gulated in HUVECs both under VEGF stimulus and PC-3S co-culture (Fig 3a), with 1.5
fold-change in both cases, associated with fatty acid oxidation, as inferred from MSEA (Fig 2).
They also show an upregulation of NAD, creatine, methionine, pantothenate, reduced gluta-
thione, cysteinylglycine and aspartate (Fig 3b), again consistent with the pathways identified
by MSEA (Fig 2). Interestingly, while NAD was upregulated in both VEGF and PC-3S condi-
tions (1.6X and 2.2X, respectively), all other metabolites were significantly upregulated only
Fig 2. Pathways associated with metabolite set enrichment analysis on HUVEC in the presence of VEGF, PC-3S
and PC-3M cells compared to control. This representation shows the pathways enriched by the identified
metabolites, irrespective of the upregulation or downregulation of the individual metabolites within the pathways
identified. This illustration is adopted from the MSEA considering only the pathways associated with metabolites of
higher fold enrichment, whose complete representation is shown in S2 Fig.
https://doi.org/10.1371/journal.pone.0192175.g002
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Fig 3. Metabolite changes due to VEGF and PC-3S cells on HUVECs, incorporated into metabolic pathways
identified by MSEA. (a) Upregulation of ALC, associated to β-oxidation of fatty acids, (b) NAD-induced pathway
alterations and other alterations only induced by PC-3S cells. 3PG– 3-phoshogluconate, αKG– α-ketoglutarate, β-Ala–
β-Alanine, ALC—acetyl L-carnitine, Asp—aspartate, CAT—Carnitine acetyltransferase, CoASH—reduced co-enzyme
A, Cys-Gly—cysteinylglycine, DMG—Dimethylglycine, FA Acyl-Coa—fatty acid acyl-CoA, Hcy—homocysteine, Gly
—glycine, GSH—glutathione reduced, Glu—glutamate, Met—methionine, OAA—oxaloacetate, PDH—pyruvate
dehydrogenase, Pyr—pyruvate, ROS—reactive oxygen species, Ser—serine, Thr—threonine, RM—control HUVECs,
VEGF—HUVECs treated with VEGF, S—HUVECs co-cultured with PC-3S. Peak area = Peak area×105 (A.U. per 106
cells).
https://doi.org/10.1371/journal.pone.0192175.g003
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upon co-culture with PC-3S cells, but not upon exposure to VEGF, although at lower fold
changes.
Hypoxanthine, guanine and AMP, were significantly altered in HUVECs exposed to VEGF,
but not co-cultured with PC-3S (Fig 4), with an upregulation of> 3X in the case of first two
metabolites and a downregulation of ~5X in AMP. This is also consistent with the MSEA
enrichment of the purine metabolism pathway in HUVECs treated with VEGF but not co-cul-
tured with PC-3 cells (Fig 2). The similarity in metabolic changes induced by VEGF and PC-
3S co-culture may be partly explained by the expression of VEGF-A by PC-3S cells (S3 Fig
shows the upregulation of VEGF-A gene expression by PC-3S cells to that of PC-3M cells).
This analysis also showed that the metabolite undergoing the most significant and specific
changes in HUVECs co-cultured with PC-3M cells was oleamide, with a 4X upregulation (Fig
5). This metabolite is not associated with any of the pathways inferred from MSEA as signifi-
cantly altered in HUVECs co-cultured with PC-3M cells (Fig 2). In addition, tryptophan, tyro-
sine and methionine showed a downregulation in HUVECs co-cultured with PC-3M cells,
which was not observed in the other conditions (Figs 2 and 5). These observations strongly
suggest that the response of ECs to epithelial CSCs, represented by PC-3M cells in our model,
Fig 4. Metabolite changes associated with purine metabolism altered with VEGF but not observed with PC-3S. The graphs show an upregulation of
hypoxanthine and guanine and downregulation of AMP. AMP—adenine monophosphate, ATP—adenine triphosphate, GMP—guanine
monophosphate, GTP—guanine triphosphate, IMP—inosine monophosphate, PRPP—Phosphoribosyl pyrophosphate, R5P –ribose-5-phosphate, ROS
—reactive oxygen species, RM—control HUVECs, VEGF—HUVECs treated with VEGF, S—HUVECs co-cultured with PC-3S. Peak area = Peak
area×105 (A.U. per 106 cells).
https://doi.org/10.1371/journal.pone.0192175.g004
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is strikingly distinct from responses to mesenchymal non-CSCs, represented by PC-3S cells, or
to the canonical angiogenic factor, VEGF.
Discussion
In order to grow and spread to other organs, cancer cells recruit ECs for tumour angiogenesis
[23] and to achieve this they induce several changes in ECs that can alter their molecular sig-
nalling and metabolic pathways. Studies on molecular angiogenesis have led to the develop-
ment of anti-angiogenic therapies in previous years, although the success rate has been low
[24]. Although EC metabolism has been under study in the past few years they have not been
particularly focused on the direct effect of cancer cells on the ECs [25]. Specific tumour sub-
niches, including those sustaining CSC, contribute to the development of vascular niche and
tumour-associated angiogenesis [26, 27]. However, whether tumour cell subpopulations with
distinct CSC or non-CSC features differentially affect endothelial cell phenotypes and metabo-
lism have not been systematically approached. We have addressed this issue by co-culturing
Fig 5. Metabolite changes and pathway enrichments identified by MSEA in RM and PC-3M-HUVEC pair. Peak area
changes of: (a) oleamide in all the conditions, and (b) tyrosine, methionine and tryptophan by PC-3M condition. DMG—
Dimethylglycine, Fum—fumarate, Hcy—homocysteine, Lys—lysine, Met—Methionine, Phe—phenylalanine, Trp—
Tryptophan, Tyr—Tyrosine, RM—control HUVECs, VEGF—HUVECs treated with VEGF, S—HUVECs co-cultured
with PC-3S cells, M—HUVECs co-cultured with PC-3M cells. Peak area = Peak area×105 (A.U. per 106 cells).
https://doi.org/10.1371/journal.pone.0192175.g005
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HUVECs with clonal tumour cell sublines with stable and clearly distinct CSC or non-CSC
properties [12].
In the present study, the application of high resolution mass spectrometry has yielded a
global metabolic fingerprint of the ECs exposed to diffusible factors produced by these distinct
cell subpopulations or to VEGF. We report that the most significantly altered metabolic
changes induced by non-metastatic and strongly mesenchymal-like PC-3S cells are similar to
those induced by VEGF, which includes metabolites such as ALC and NAD. These similarities
may be partly explained by the observation that PC-3S cells express VEGF-A at levels signifi-
cantly higher than PC-3M cells. Similarly, it has been found in vivo that the low metastatic
DU145 cell line secretes VEGF at significantly higher levels than PC-3M cells [28].
One of the most significant changes observed in HUVECs common to VEGF treatment
and PC-3S co-culture was the upregulation of ALC. This metabolite is produced from carni-
tine and acetyl-coA by carnitine acetyltransferase (CAT) and thus is closely associated to fatty
acid oxidation, which generates acetyl-CoA. This reaction is reversible and carnitine produced
from the breakdown of ALC can be recycled back into the cytoplasm to transport more fatty
acid acyl-coA’s for β-oxidation [29], which in turn produces more acetyl-CoA. Fatty acid oxi-
dation has been found to be important in ECs mainly due to its contribution to dNTP synthe-
sis and driving endothelial cell proliferation for vessel sprouting [30]. Further, ALC has been
reported to possess therapeutic implications in protecting vascular function against oxidative
stress [31] and in protecting endothelial structure in blood-brain barrier [32].
A second metabolite strongly upregulated in HUVECs by both VEGF and PC-3S cells was
NAD, a major contributor to a variety of metabolic pathways (glycolysis, nicotinamide metab-
olism, citric acid cycle, ketone body metabolism and gluconeogenesis). Glycolysis has been
found to be important for endothelial cell survival, proliferation and other angiogenic activities
such as migration and sprouting [33, 34]. Endothelial mitochondrial function is not reported
to be a significant or preferred pathway for ATP production, compared to glycolysis, although
it has been reported to be useful during cellular stress or when glycolysis is compromised [35,
36], in addition to the angiogenesis stimulation by non-toxic levels of mitochondrial ROS [37,
38]. The interpretation of these observations require a certain degree of caution, given that
related reactions involve inter-conversions between the oxidized and the reduced forms of
NAD. The reduced NADH form is unstable and hence the observed NAD levels are likely to
reflect a mixture of both forms, which makes NAD a relatively unreliable biomarker.
Importantly, PC-3S cells induced the upregulation of metabolites not significantly affected
by VEGF, while VEGF, but not PC-3S cells, strongly altered purine metabolism. These differ-
ences between the two conditions are likely explained by the production by PC-3S cells of dif-
fusible factors other than VEGF, yet to be identified. VEGF is a potent regulator of endothelial
cell proliferation and angiogenesis [39] and in order to proliferate, cells have to generate an
excess of nucleotide components. Purine metabolism is important for the production of DNA
and RNA components. Moreover, they can also generate xanthine oxidase-derived ROS. In
contrast, it has been shown that VEGF can induce the production of mitochondrial ROS
which in turn can function as signalling factors for mediating endothelial cell migration [40].
ROS-mediated angiogenesis is also observed by NAD(P)H-generated ROS [41]. To our knowl-
edge, the changes in hypoxanthine, guanine and AMP induced by VEGF in ECs have not been
reported previously. Hence, the changes in purine metabolism induced by VEGF are explained
as associated with a concomitant induction of endothelial cellular proliferation and may also
be related to the generation of ROS.
The most remarkable finding reported herein is the extremely contrasting metabolic
response of HUVECs to two tumour cell subpopulations displaying distinct phenotypes. Thus,
while the non-metastatic PC-3S cells induced metabolic changes in HUVECs that were largely
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similar to those induced by VEGF, the highly metastatic PC-3M cells, enriched in CSCs,
induced a completely distinct set of metabolic alterations. These included a strong upregula-
tion of oleamide and a significant, but of lower fold change, downregulation of tryptophan,
tyrosine and methionine.
Oleamide is a primary fatty acid amide, reported to possess signalling [42] and sleep-induc-
ing properties [43] and has vasodilatory effects [44, 45]. In addition it is found to regulate cel-
lular gap junctions in various types of cells [46–49]. The gap junction inhibition, when
oleamide is supplemented as a therapeutic agent, leads to an anti-metastatic effect by inhibiting
the connexin proteins that enable gap junction-mediated intercellular communications during
metastasis [50, 51]. Furthermore, oleamides are suspected to play a role in preventing the
spread of apoptotic proteins or cell death signals from a damaged cell to a neighbour through
cellular junctions [52, 53]. Endothelial cell damage and apoptosis have been found to be
induced by tumour cells during metastasis, in order to extravasate from the blood vessels to
invade secondary metastatic sites [54, 55]. Thus, the intracellular production of oleamide
shows an endothelial response to the metastatic potential of PC-3M cells. Although oleamide
has been reported in a variety of biological matrices to include human breast cancer cells [56],
mouse neuroblastoma cells [57], human serum [58] and rat cerebral spinal fluid [59], it is yet
to be reported in ECs.
PC-3M cells are also reported to be metabolically different from the PC-3S sub-type, in
which the PC-3M cells depend mainly on aerobic glycolysis and use mitochondrial substrates
as alternative energy sources, while the PC-3S cells rely on mitochondrial oxidation for energy
[60]. Hence PC-3M cells produce high amounts of lactate compared to PC-3S cells [60]. ECs
reportedly take up lactate which functions as signalling molecule for HIF-1 activation, consec-
utively increasing endothelial cell migration, tube formation and angiogenesis [61, 62]. Thus
the unique properties of the two PC3 sub-types explain their distinct metabolic shifts in
HUVECs.
A tumour mass can have different kinds of tumour cells co-existing within the vascular
niche [63, 64] and the heterogeneous tumour sub-types with EMT and CSC traits have been
reported to initiate and promote angiogenesis by the production of VEGF [65]. Further, it has
also been reported that the dormant niche and the micrometastatic outgrowths are promoted
by different kinds of vasculature systems, where the ECs within the stable microvasculature
secrete thrombospondin-1 that promotes the dormancy of the tumour cells, while the sprout-
ing neovasculature secretes periostin and transforming growth factor-β1 (TGF-β1) favouring
proliferation of the metastatic tumour cells [66]. This shows that a vascular heterogeneity exists
within tumour subtypes. In our study the strikingly different metabolic changes observed
within the ECs grown with EMT- and CSC-like prostate cancer cells strongly support differing
behaviour of the vasculatures within the tumour subtypes.
Conclusion
In this study, we have discovered that the ECs reprogram their metabolism by displaying
unique metabolic responses to diffusible factors produced either by a CSC-enriched tumour
cell subpopulation or by a non-CSC tumour cell subpopulation. To our knowledge, this is the
first time that tumour heterogeneity has been reported to influence endothelial cell metabo-
lism, and thus presumably functions, through distinct and largely non-overlapping responses
either to CSC or to non-CSCs. Our approaches, which include the use of adequate cell models,
lay the foundations for an improved understanding of tumour-associated angiogenesis that
takes into account distinct tumour cell subpopulations and their specific interactions with, and
modulation of, endothelial cells.
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